Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor PK in Infants and Toddlers with Sickle Cell Disease
NCT03492931Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of ticagrelor in sickle cell disease (SCD), sponsored by AstraZeneca. Primary endpoints: Peak Plasma Concentration of Ticagrelor at 6 hours, Area Under Plasma Concentration Curve at 6 hours and 1 more. Started Mar 2018; status: completed.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03492931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492931.